An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
Latest Information Update: 02 Feb 2024
Price :
$35 *
At a glance
- Drugs Navtemadlin (Primary) ; TL 895 (Primary) ; Loperamide; Ondansetron
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Telios Pharmaceuticals
- 31 Jan 2024 This study has been completed in France, according to European Clinical Trials Database record.
- 06 Sep 2023 This trial has been completed in Italy.
- 15 Mar 2023 This trial has been completed in Austria according to European Clinical Trials Database record.